BACKGROUND: An estimated 2·5 billion people are at risk of dengue. Incidence of dengue is especially high in resource-constrained countries, where control relies mainly on insecticides targeted at larval or adult mosquitoes. We did epidemiological and economic assessments of different vector control strategies. METHODS: We developed a dynamic model of dengue transmission that assesses the evolution of insecticide resistance and immunity in the human population, thus allowing for long-term evolutionary and immunological effects of decreased dengue transmission. We measured the dengue health burden in terms of disability-adjusted life-years (DALYs) lost. We did a cost-effectiveness analysis of 43 insecticide-based vector control strategies, including strategies targeted at adult and larval stages, at varying efficacies (high-efficacy [90% mortality], medium-efficacy [60% mortality], and low-efficacy [30% mortality]) and yearly application frequencies (one to six applications). To assess the effect of parameter uncertainty on the results, we did a probabilistic sensitivity analysis and a threshold analysis. FINDINGS: All interventions caused the emergence of insecticide resistance, which, with the loss of herd immunity, will increase the magnitude of future dengue epidemics. In our model, one or more applications of high-efficacy larval control reduced dengue burden for up to 2 years, whereas three or more applications of adult vector control reduced dengue burden for up to 4 years. The incremental cost-effectiveness ratios of the strategies for two high-efficacy adult vector control applications per year was US$615 per DALY saved and for six high-efficacy adult vector control applications per year was $1267 per DALY saved. Sensitivity analysis showed that if the cost of adult control was more than 8·2 times the cost of larval control then all strategies based on adult control became dominated. INTERPRETATION: Six high-efficacy adult vector control applications per year has a cost-effectiveness ratio that will probably meet WHO's standard for a cost-effective or very cost-effective intervention. Year-round larval control can be counterproductive, exacerbating epidemics in later years because of evolution of insecticide resistance and loss of herd immunity. We suggest the reassessment of vector control policies that are based on larval control only. FUNDING: The Fulbright Programme, CAPES (Brazilian federal agency for post-graduate education), the Miriam Burnett trust, and the Notsew Orm Sands Foundation.
BACKGROUND: An estimated 2·5 billion people are at risk of dengue. Incidence of dengue is especially high in resource-constrained countries, where control relies mainly on insecticides targeted at larval or adult mosquitoes. We did epidemiological and economic assessments of different vector control strategies. METHODS: We developed a dynamic model of dengue transmission that assesses the evolution of insecticide resistance and immunity in the human population, thus allowing for long-term evolutionary and immunological effects of decreased dengue transmission. We measured the dengue health burden in terms of disability-adjusted life-years (DALYs) lost. We did a cost-effectiveness analysis of 43 insecticide-based vector control strategies, including strategies targeted at adult and larval stages, at varying efficacies (high-efficacy [90% mortality], medium-efficacy [60% mortality], and low-efficacy [30% mortality]) and yearly application frequencies (one to six applications). To assess the effect of parameter uncertainty on the results, we did a probabilistic sensitivity analysis and a threshold analysis. FINDINGS: All interventions caused the emergence of insecticide resistance, which, with the loss of herd immunity, will increase the magnitude of future dengue epidemics. In our model, one or more applications of high-efficacy larval control reduced dengue burden for up to 2 years, whereas three or more applications of adult vector control reduced dengue burden for up to 4 years. The incremental cost-effectiveness ratios of the strategies for two high-efficacy adult vector control applications per year was US$615 per DALY saved and for six high-efficacy adult vector control applications per year was $1267 per DALY saved. Sensitivity analysis showed that if the cost of adult control was more than 8·2 times the cost of larval control then all strategies based on adult control became dominated. INTERPRETATION: Six high-efficacy adult vector control applications per year has a cost-effectiveness ratio that will probably meet WHO's standard for a cost-effective or very cost-effective intervention. Year-round larval control can be counterproductive, exacerbating epidemics in later years because of evolution of insecticide resistance and loss of herd immunity. We suggest the reassessment of vector control policies that are based on larval control only. FUNDING: The Fulbright Programme, CAPES (Brazilian federal agency for post-graduate education), the Miriam Burnett trust, and the Notsew Orm Sands Foundation.
Authors: Michael J Bangs; Ria P Larasati; Andrew L Corwin; Suharyono Wuryadi Journal: Southeast Asian J Trop Med Public Health Date: 2006-11 Impact factor: 0.267
Authors: M N Burattini; M Chen; A Chow; F A B Coutinho; K T Goh; L F Lopez; S Ma; E Massad Journal: Epidemiol Infect Date: 2007-05-31 Impact factor: 2.451
Authors: Isabela Reis Montella; Ademir Jesus Martins; Priscila Fernandes Viana-Medeiros; José Bento Pereira Lima; Ima Aparecida Braga; Denise Valle Journal: Am J Trop Med Hyg Date: 2007-09 Impact factor: 2.345
Authors: Jose A Suaya; Donald S Shepard; Moh-Seng Chang; Mariana Caram; Stefan Hoyer; Duong Socheat; Ngan Chantha; Michael B Nathan Journal: Trop Med Int Health Date: 2007-09 Impact factor: 2.622
Authors: Blas Armien; Jose A Suaya; Evelia Quiroz; Binod K Sah; Vicente Bayard; Loyd Marchena; Cornelio Campos; Donald S Shepard Journal: Am J Trop Med Hyg Date: 2008-09 Impact factor: 2.345
Authors: Marli Tenório Cordeiro; Ana Maria Silva; Carlos A A Brito; Eduardo J M Nascimento; Maria Cecilia F Magalhães; Georgia F Guimarães; Norma Lucena-Silva; Eduardo M Freese de Carvalho; Ernesto T A Marques Journal: Am J Trop Med Hyg Date: 2007-12 Impact factor: 2.345
Authors: Jelte Elsinga; Masja Schmidt; Erley F Lizarazo; Maria F Vincenti-Gonzalez; Zoraida I Velasco-Salas; Luzlexis Arias; Johannes G M Burgerhof; Adriana Tami Journal: Am J Trop Med Hyg Date: 2018-05-24 Impact factor: 2.345
Authors: Zoraida I Velasco-Salas; Gloria M Sierra; Diamelis M Guzmán; Julio Zambrano; Daniel Vivas; Guillermo Comach; Jan C Wilschut; Adriana Tami Journal: Am J Trop Med Hyg Date: 2014-09-15 Impact factor: 2.345
Authors: Alexandre R Marra; Gustavo Faissol Janot de Matos; Renata Donato Janeri; Patricia Sousa Machado; Claudio Schvartsman; Oscar Fernando Pavão Dos Santos Journal: BMC Res Notes Date: 2011-09-08
Authors: Kathryn A Hanley; Thomas P Monath; Scott C Weaver; Shannan L Rossi; Rebecca L Richman; Nikos Vasilakis Journal: Infect Genet Evol Date: 2013-03-20 Impact factor: 3.342